Contrasting Novogen Limited (NVGN) and ImmunoGen (IMGN)

ImmunoGen (NASDAQ: IMGN) and Novogen Limited (NASDAQ:NVGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitabiliy, institutional ownership, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for ImmunoGen and Novogen Limited, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoGen 1 4 3 0 2.25
Novogen Limited 0 0 1 0 3.00

ImmunoGen currently has a consensus price target of $4.60, indicating a potential upside of 0.44%. Novogen Limited has a consensus price target of $5.00, indicating a potential upside of 482.75%. Given Novogen Limited’s stronger consensus rating and higher probable upside, analysts plainly believe Novogen Limited is more favorable than ImmunoGen.


This table compares ImmunoGen and Novogen Limited’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmunoGen -244.76% N/A -60.22%
Novogen Limited N/A N/A N/A

Institutional and Insider Ownership

73.9% of ImmunoGen shares are held by institutional investors. Comparatively, 2.2% of Novogen Limited shares are held by institutional investors. 5.0% of ImmunoGen shares are held by insiders. Comparatively, 1.0% of Novogen Limited shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ImmunoGen and Novogen Limited’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ImmunoGen $51.80 million 7.90 -$104.78 million ($1.61) -2.84
Novogen Limited $3.59 million 4.62 -$7.94 million N/A N/A

Novogen Limited has higher revenue, but lower earnings than ImmunoGen.

Risk and Volatility

ImmunoGen has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500. Comparatively, Novogen Limited has a beta of -0.37, suggesting that its stock price is 137% less volatile than the S&P 500.


ImmunoGen beats Novogen Limited on 6 of the 11 factors compared between the two stocks.

ImmunoGen Company Profile

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Novogen Limited Company Profile

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company’s product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company’s target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells’ actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer.

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply